Steve Jones
Freelance journalist, contributor to @cannabiz_au, @mumbrellanews and @medicalrepublic
Articles
-
3 days ago |
cannabiz.com.au | Steve Jones
The fundamentals of Vitura Health are “back on track” with its Q4 performance forecast to hit all business targets, chief executive Geoff Cockerill has said. In a trading update, the company said revenue growth in the final quarter of FY25 should support an annualised increase of 11%, while margins and a reduction in operational expenditure are forecast to rise 3% and improve 10% respectively, in line with its FY25 goals.
-
1 week ago |
cannabiz.com.au | Steve Jones
A new cultivation lobbying group has formed in Australia and called for “urgent action” to “save the local medicinal cannabis cultivation industry from collapse”. The Australian Cannabis Cultivators Guild, spearheaded by Hale Farm director Cade Turland, has sent a letter to federal health minister Mark Butler warning of “catastrophic failures across local cultivators” unless imports are restricted and a “domestic-first” policy is adopted which allows cultivators to “grow their permitted amounts”.
-
1 week ago |
cannabiz.com.au | Martin Lane |Steve Jones
Althea Group Holdings (AGH) is selling its pharmaceutical assets to Tasmanian Botanics for A$1 million in a deal that will involve a revenue-sharing arrangement on residual inventory sales. Althea said the transaction “relates solely to the Althea trademarks, brand, goodwill, website, phone number, and pharmacy/prescriber data of the pharmaceutical division”.
-
1 week ago |
cannabiz.com.au | Steve Jones
With Althea calling time on its Australian pharma business and selling the assets to Tasmanian Botanics, Cannabiz chief correspondent Steve Jones analyses what went wrong for one of the local industry’s early movers. At the Althea Group Holdings (AGH) annual general meeting in November 2022, the company’s chief executive, Josh Fegan, was in particularly bullish mood.
-
1 week ago |
cannabiz.com.au | Martin Lane |Steve Jones
Althea Group Holdings (AGH) has signed a binding term sheet to sell its pharmaceutical assets to Tasmanian Botanics for A$1 million, plus a revenue-sharing arrangement on residual inventory sales. AGH flagged a potential sale of the division as part of a “comprehensive strategic review” in a quarterly update to the ASX last week.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 890
- Tweets
- 1K
- DMs Open
- No
@FamiilyAu Hi, I'm a journalist trying to find a contact email address or phone number for the party. Can you help please? Many thanks
I'm attending this event. RT if you think others will find this helpful 🙌 https://t.co/iQ47zbGq8J #australiancannabissummit2023
ECS Botanics strikes $11.9m dried flower offtake deals https://t.co/hcA8CzSkQI